CardieX Limited (AU:CDX) has released an update.
CardieX Limited has secured a new R&D Term Loan Facility of $1.12 million from Mitchell Asset Management to support its research and development efforts and working capital needs. The loan, expected to be repaid with future R&D Tax Incentive refunds, brings CardieX’s total outstanding principal to MAM to $2 million. The funds will help the company continue developing medical technologies for cardiovascular and vascular health disorders.
For further insights into AU:CDX stock, check out TipRanks’ Stock Analysis page.
